3-Amino-1,2-benzisoxazoles: A new family of potent inhibitors of LTB4 binding to the human neutrophils

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 4, 1997, Pages 389-392

  Suh, Hongsuk ^a   Jeong, Soo Jeong ^a   Han, Yong Nam ^b   Lee, Hwa Jin ^c   Ryu, Jae Ha ^c  

^a Pusan National University   (South Korea)

^b Seoul National University   (South Korea)

^c Sookmyung Women's University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HS 1141; ISOXAZOLE DERIVATIVE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MOXILUBANT MALEATE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUTROPHIL; NORMAL HUMAN;

EID: 0031576827     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00025-5     Document Type: Article

References (32)

1. 1. Ford-Hutchinson, A.W.; Bray, M.; Doig, M.; Shipley, M.; Smith, M.J. Nature (London) 1980, 286, 264-265.
2. 2. Goldman, D.W.; Gifford, L.A.; Marotti, T.,; Koo, C.H.; Goetzl, E.J. Fed. Proc. 1987, 46, 200-203.
3. 3. Palmblad, J.; Malmster, C.; Uden, A.; Radmark, O.; Engstedt, L.; Samuelson, B. Blood 1981, 58, 658-661.
4. 4. Showell, H.J.; Naccache, P.H.; Borgeat, P.; Picard, S.; Vallerand, P.; Becher, E.L.; Sha'afi, R.I. J. Immuinol. 1982, 128, 811-816.
5. 5. Kragballe, K.; Voorhees, J. J. Acta Derm. Venereol. (Stockn) 1985, Suppl. 120, 12-17.
6. 6. Stenson, D.W. J. Gastroenterol. 1990, 25 (Suppl. 172) 13-18.
7. 7. Davidson, E.M.; Rae, S.A.; Smith, M.J.H. Annu. Rheum. Dis. 1983, 43, 677-679.
8. 8. Rae, S.A.; Davidson, E.M.; Smith, M.J.H. Lancet 1982, 2, 1122-1124.
9. 9. Wardlaw, J.J.; Hay, H.; Cromwell, O.; Collins, J.V.; Kay, A.B. J. Allergy Clin. Immunol. 1989, 84, 12-26.
10. 10. Cromwell, O.; Walport, M.J.; Morris, H.R.; Taylor, G.W.; Hodson, M.E.; Batten, J.; Kay, A.B. Lancet 1981, 2, 164-165.
11. 11. Antonelli, M.; Bufi, M.; De Blasi, R.A.; Crimi, G.; Conti, G.; Mattia, C.; Vivino, G.; Lenti, L.; Lombardi, D.; Dotta, A. Intensive Care Med. 1989, 15, 296-301.
12. 12. Katsura, K.; Minamisawa, H.; Katayama, Y.; Shimizu, J.; Goto, T.; Urushiyama, K.; Terashi, A.; Kanda, Y.; Yoshino, Y. Prostaglandins 1988, 36, 655-665.
13. 13. Namiki, M.; Iganashi, Y.; Sakamato, K.; Koga, Y. Biochem. Biophys. Res. Commun. 1986, 138, 540-546.
14. 14. Morris, J.; Wishka, D.G. Tetrahedron Lett. 1988, 29, 143-146.
15. 15. (a) Herron, D.K.; Bollinger, N.G.; Swanson-Bean, D.; Jackson, W.T.; Froelich, L.L.; Goodson, T. FASEB J. 1988, 2, A1110.
16. (b) Herron, D. K.; Goodson, T.; Bollinger, N.G.; Swanson-Bean, D.; Wright, I.G.; Staten, G.S.; Thompson, A.R.; Froehlich, L.L.; Jackson, W.T. J. Med. Chem. 1992, 35, 1818-1828.
17. (c) Gapinski, D.m.; Mallett, B.E.; Froelich, L.L.; Boyd, R.J.; Jackson, W.T. FASEB J. 1988, 2, A1110
18. (d) Gapinski, D.M.; Mallett, B.E.; Froelich, L.L.; Jackson, W.T. J. Med. Chem. 1990, 33, 2798-2807.
19. 16. Djuric, S.W.; Collins, P.W.; Jones, P.H.; Shone, R.L.; Tsai, B.S.; Fretland, D.J.; Butchko, G.M.; Villani-Price, D.; Keith, R.H.; Zemaitis, J.M.; Metcalf, L.; Bauer, R.F. J. Med. Chem. 1989, 32, 1145-1147.
20. 17. Konno, M.; Sakuyama, S.; Nakae, T.; Hamanaka, N.; Miyamoto, T.; Kawasaki, A. Adv. Prostaglandin, Thromboxane Leukotriene Res. 1991, 21, 411-414.
21. 18. Showell, H.J.; Pettipher, E.R.; Cheng, J.B.; Breslow, R.; Conklyn, M.J.; Farrell, C.A.; Hingorani, G.P.; Salter, E.D.; Hackman, B.C.; Wimberly, D.J.; Doherty, N.S.; Melvin, L.S.; Reiter, L.A.; Biggers, M. S.; Koch, K.J. Phamacol. Exper. Ther. 1995, 273, 176-184.
22. 19. (a) Morrissey, M.M.; Suh, H. W.O. Patent 94/11341, 1994.
23. (b) Suh, H. U.S.Patent 5 455 274, 1995.
24. (c) Fujimoto, R.A.; Main, A.J.; Barsky, L.I.; Morrissey, M.; Cadilla, R.; Boehm, C.; Zhang, Y.; Suh, H.; Boxer, J.B.; Powers, D.B.; Doti, R.A.; Healy, C.T.; Seligmann, B.E.; Uziel-Fusi, S.; Jarvis, M.F.; Sills, M.A.; Jackson, R.H.; Lipson, K.E.; Chin, M.H.; Pellas, T.C.; Pastor, G.; Freyer, L.R.; Raychaudhuri, A.; Kotyuk, B.L. 7th International Conference of the Inflammation Research Association, White Haven, PA, 1994; p29.
25. (d) Morgan, J.; Stevens, R.; Uziel-Fusi, S.; Seligmann, B.E.; Haston, W.; Lau, H.; Hayes, M; Hirschhorn, W.L.; Saris, S.; Piraino, A. Clin. Pharmacol. Ther. 1994, 55, 199.
26. 4 Antagonists, New York, NY, 1994.
27. 20. Shutske, G.M.; Kapples, K.J. J. Heterocyclic Chem. 1989, 26, 1293-1298.
28. 3) δ 20.7, 28.9, 48.3, 55.8, 64.8, 65.4, 93.6, 109.4, 109.9, 112.6, 112.9, 118.1, 120.6, 131.7, 148.6, 149.2, 157.8, 161.4, 164.6, 170.8.
29. 7 cells/ml in HBSS (Hank's balanced salt solution, Gibco).
30. 4 binding at various concentrations.
31. 24. Boyum, A. Scand. J. Clin. Lab. Invest. 1989, 21, Suppl. 97, 77-89.
32. 25. Tsai, B.S.; Villani-Price, D.; Keith, R.H.; Zemaitis, J.M.; Bauer, R. F.; Leonard, R.; Djuric, S.W.; Shone, R.L. Prostaglandins, 1989, 38, 655-674.